Subclinical Thyroid Dysfunction and the Risk for Fractures: A Systematic Review and Meta-analysis

Christina D. Wirth, MD, Manuel R. Blum, MD, Bruno R. da Costa, PhD, Christine Baumgartner, MD, Tinh-Hai Collet, MD, Marco Medici, MD, MSc, Robin P. Peeters, MD, PhD, Drahomir Aujesky, MD, MSc, Douglas C. Bauer, MD, and Nicolas Rodondi, MD, MAS

University of Bern, Bern, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland; Erasmus Medical Center, Rotterdam, the Netherlands; and University of California, San Francisco, San Francisco, California

Abstract

Background—Data on the association between subclinical thyroid dysfunction and fractures conflict.

Purpose—To assess the risk for hip and nonspine fractures associated with subclinical thyroid dysfunction among prospective cohorts.

Data Sources—Search of MEDLINE and EMBASE (1946 to 16 March 2014) and reference lists of retrieved articles without language restriction.

Study Selection—Two physicians screened and identified prospective cohorts that measured thyroid function and followed participants to assess fracture outcomes.
Data Extraction—One reviewer extracted data using a standardized protocol, and another verified data. Both reviewers independently assessed methodological quality of the studies.

Data Synthesis—The 7 population-based cohorts of heterogeneous quality included 50,245 participants with 1966 hip and 3281 nonspine fractures. In random-effects models that included the 5 higher-quality studies, the pooled adjusted hazard ratios (HRs) of participants with subclinical hyperthyroidism versus euthyroidism were 1.38 (95% CI, 0.92 to 2.07) for hip fractures and 1.20 (CI, 0.83 to 1.72) for nonspine fractures without statistical heterogeneity (P = 0.82 and 0.52, respectively; I² = 0%). Pooled estimates for the 7 cohorts were 1.26 (CI, 0.96 to 1.65) for hip fractures and 1.16 (CI, 0.95 to 1.42) for nonspine fractures. When thyroxine recipients were excluded, the HRs for participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) for hip fractures and 1.43 (CI, 0.73 to 2.78) for nonspine fractures. For participants with subclinical hypothyroidism, HRs from higher-quality studies were 1.12 (CI, 0.83 to 1.51) for hip fractures and 1.04 (CI, 0.76 to 1.42) for nonspine fractures (P for heterogeneity = 0.69 and 0.88, respectively; I² = 0%).

Limitations—Selective reporting cannot be excluded. Adjustment for potential common confounders varied and was not adequately done across all studies.

Conclusion—Subclinical hyperthyroidism might be associated with an increased risk for hip and nonspine fractures, but additional large, high-quality studies are needed.

Primary Funding Source—Swiss National Science Foundation.

About 10% of women and 3% of men older than 60 years have subclinical hypothyroidism (1-3), and prevalence increases with age. Subclinical hypothyroidism is defined as elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (FT₄) levels (4). Subclinical hyperthyroidism, defined as decreased TSH and normal FT₄ and triiodothyronine (T₃) levels (4), is less common and affects about 1.5% of women and 1% of men older than 60 years. Subclinical thyroid dysfunction has previously been associated with an increased risk for coronary heart disease and heart failure events (5-7).

Thyroid hormones influence the homeostasis and remodeling of bone (8). Overt hyperthyroidism is a risk factor for fractures (9). A few observational studies have also found an increased risk for fracture in persons with overt hypothyroidism (10, 11).

The association between subclinical thyroid dysfunction and fractures remains unclear. A prospective cohort study of 3567 elderly participants found an increased risk for hip fractures in men with endogenous subclinical hyperthyroidism and a similar trend in women, whereas subclinical hypothyroidism was associated with an increased risk for hip fracture in men only (12). Conversely, a case–cohort study of 1526 ambulatory men older than 65 years found no significant relationship between subclinical hyperthyroidism and fractures, but low-normal TSH levels were significantly associated with an increased risk for hip fractures (13). Other prospective studies (14) did not adjust for common relevant potential confounders between subclinical thyroid dysfunction and fractures, such as age, sex, body mass index, smoking, and corticosteroid use (15-24). Two meta-analyses of postmenopausal women with exogenous subclinical hyperthyroidism due to thyroxine substitution showed a reduction in bone mineral density (BMD), which is a surrogate marker for osteoporosis (25,
To our knowledge, no meta-analysis has been done on the risk for fractures related with subclinical thyroid dysfunction. Therefore, we did a meta-analysis to determine whether subclinical thyroid dysfunction and TSH levels were associated with an increased risk for fractures in prospective cohort studies.

**Methods**

**Data Sources and Searches**

We followed a standardized protocol to do this meta-analysis. Similar to our previous study (27), we conducted a systematic literature search for articles in any language on the association between subclinical thyroid dysfunction (both subclinical hypothyroidism and hyperthyroidism) and fractures published between 1946 and 16 March 2014 in the MEDLINE and EMBASE databases. In Ovid MEDLINE, we used the following broadly defined Medical Subject Headings: thyroid diseases, hypothyroidism, hyperthyroidism, thyroid hormones, thyrotropin, subclinical hyperthyroidism, subclinical hypothyroidism, subclinical dysthyroidism, subclinical thyroid, and fractures or osteoporosis. These headings were combined with the filter designed by *British Medical Journal* knowledge information specialists to identify randomized, controlled trials; cohorts; and case–control studies without year limitation or exclusion of comments, editorials, meta-analyses, practice guidelines, reviews, letters, journal correspondences, books, conference papers, or animal studies (28). We used a similar procedure in EMBASE. We also searched the bibliographies of key articles in the field and those included in this review, and we contacted authors for unpublished studies.

**Study Selection**

Similar to our previous study (27), 2 authors independently screened the abstracts and titles of the search results and retained articles on prospective cohorts studying the association between thyroid dysfunction and osteoporotic fractures. The same reviewers independently assessed the remaining full-text articles for eligibility on the basis of predefined criteria. Any disagreement was resolved by discussion with a third author. Because some prospective studies that measured thyroid function and assessed multiple outcomes may not have reported fracture outcomes in the abstract, we also assessed the full text and tables for reported fracture data in these studies. We included only studies that fulfilled the following a priori–defined criteria: measurement of thyroid function, prospective follow-up of participants, assessment of fracture outcomes, comparison group with euthyroidism, and provision of hazard ratios (HRs) or sufficient data to calculate them. We excluded studies that examined only persons with a history of overt thyroid dysfunction or thyroid cancer.

We considered nonspine, hip, and any fractures, but we excluded spine fractures because vertebral fracture age is difficult to assess without serial radiographs and the accuracy of self-report is poor (29).

Agreement among reviewers was 97.9% for the first screening of titles and abstracts (κ = 0.69) and 100% for full-text screening (κ = 1.0).
Data Extraction and Quality Assessment

We used a standardized data abstraction form to extract information about participant characteristics, the criteria used to define subclinical thyroid dysfunction, and fractures. We evaluated study quality using slightly up-dated criteria (27, 30), including inclusion of testing for the assumption of proportional hazards. One physician reviewer extracted data, and another checked data. We assessed key indicators for the quality of the cohort studies (31, 32): the population studied (convenience sample vs. population-based, which was defined as a random sample of the general population) and methods of fracture ascertainment and adjudication (considered adequate if done by an expert panel blinded to thyroid status using a clear outcome definition); assessment of the proportional hazard assumption; completeness of follow-up; and adjustment for potential confounders. We defined age, sex, body mass index, smoking, and corticosteroid use (15-24) as common relevant potential confounders for the relationship between subclinical thyroid dysfunction and fractures based on a literature search considering their prevalence and strength of association with fractures and thyroid dysfunction. We required adjustment for most of these risk factors and lack of violation of the proportional hazard assumption for a study to be rated as higher quality. If an article did not clearly mention one of these criteria, we considered that it had not been done. Two reviewers independently rated all studies for quality, and disagreement was resolved with a third reviewer.

We contacted the authors of all cohorts to request more detailed data on the association between subclinical thyroid dysfunction and fractures. We used the most adjusted HRs and 95% CIs available.

Data Synthesis and Statistical Analysis

We used TSH cutoff levels as reported by each cohort. If not otherwise specified by a cohort, we used a common definition of subclinical thyroid disease based on expert reviews (4, 33) and the definition used in the Cardiovascular Health Study (12, 34), as done in previous articles (5-7). Subclinical hypothyroidism was defined as a TSH level greater than 4.5 to 20.0 mIU/L and an FT4 level in the reference range. Subclinical hyperthyroidism was defined as a TSH level less than 0.45 mIU/L and an FT4 level in the reference range. Euthyroidism was defined as a TSH cutoff level from 0.45 to 4.5 mIU/L. For FT4, we used study-specific cutoff levels because these measurements show greater intermethod variation than TSH. Three studies (14, 35, 36) did not include FT4 in their definition of subclinical thyroid dysfunction. Two of these studies (35, 36) were included in the main analysis of the higher-quality studies, but we did a sensitivity analysis excluding studies without FT4 measurement or with abnormal FT4 because some participants may have overt thyroid dysfunction. Two of these studies differentiated between low and suppressed TSH levels (14, 35). We used data from the group with low but not suppressed TSH levels because, according to unpublished data in our previous individual-participant data analysis (7), about one fourth of persons with a TSH level less than 0.1 mIU/L had overt hyperthyroidism, but only about 5% of those with a TSH level greater than 0.1 mIU/L had overt hyperthyroidism.

We qualitatively synthesized data and assessed which participants were included, the definition of thyroid dysfunction, and which types of fractures were studied. First, for the
higher-quality studies, we calculated pooled estimates and 95% CIs of the risk for subclinical hyperthyroidism and hypothyroidism on hip and nonspine fractures using random-effects models based on the Knapp–Hartung approach (37) to account for the uncertainty associated with statistical heterogeneity (tau-square estimation) and the small number of studies included (38). Second, we assessed overall pooled estimates for all studies using the same approach. Because the Cardiovascular Health Study only reported estimates stratified by sex, we used fixed effects to combine these estimates before pooling them with other cohorts (12).

To assess heterogeneity among studies, we quantified the $Q$ statistic with a conservative $P$ value of 0.10 (39) and used the $I^2$ statistic, which describes the total variation across studies attributable to heterogeneity rather than chance ($I^2 > 50\%$, indicating at least moderate statistical heterogeneity) (40). To explore sources of heterogeneity, we did several predefined sensitivity analyses from all included studies using random-effects models. We also did analyses stratified by age and sex. Stratified analysis were accompanied by interaction tests based on $Z$ scores, which are defined as the difference in effect estimates between strata divided by the SE of the difference.

We used an adjusted rank correlation test to assess for publication bias (41). However, graphical and statistical methods may not be reliable because of their limited power due to the small number of studies included in our meta-analysis (42). All analyses were done by using Stata, version 12.1 (StataCorp, College Station, Texas).

Role of the Funding Source
The funding source had no role in defining questions, abstracting data, synthesizing results, or preparing or deciding to submit the manuscript for publication.

RESULTS

Study Selection
Of the 1185 reports initially identified, 1132 were excluded on the basis of their title and abstract because they were unrelated to the association between subclinical thyroid dysfunction and fractures or were not prospective studies with measurement of thyroid hormones (Appendix Figure 1, available at www.annals.org). After full-text review of the 53 selected articles, we excluded 46 studies that did not meet the inclusion criteria (Appendix Table, available at www.annals.org). Seven studies met all eligibility criteria and were included in the analyses.

Study Characteristics
Table 1 shows the study characteristics of included studies in our meta-analysis and the HRs for the associations between subclinical thyroid dysfunction and hip and nonspine fractures. These 7 studies included 50 245 participants with 1966 hip and 3281 nonspine fractures. Four cohorts included men and women, 2 cohorts included only women, and 1 cohort included only men. Follow-up ranged from 3.7 to 13 years. One cohort included only participants treated with thyroid hormone, and 2 cohorts excluded all treated participants.
Most cohorts assessed subclinical hyperthyroidism and hypothyroidism, and 1 cohort assessed only subclinical hyperthyroidism. All studies used a second- or third-generation TSH assay.

Description of Study Quality

The quality of included studies was heterogeneous. All studies were population-based (Table 2). Four used a formal adjudication procedure for fracture ascertainment, and 3 reported adjudication of fractures without knowledge of thyroid status. Five cohorts provided information on loss to follow-up, which was 2% or less. All cohorts reported nonviolation of the proportional hazard assumption. Table 2 indicates the confounders that were adjusted for by the different studies by using appropriate multivariate analyses. Five of the studies reported HRs with adjustment for most of the aforementioned common relevant confounders, but 2 studies lacked such adjustment (14, 46). On the basis of the quality assessment in Table 2, with the request of the adjustment for most of these confounders and lack of violation of the proportional hazard assumption, 5 studies were rated higher quality and thus were included in the main pooled analysis (12, 13, 35, 36, 44).

Subclinical Hyperthyroidism and Hip Fractures

All studies found an increased risk for hip fractures associated with subclinical hyperthyroidism, and the Sheffield cohort had a statistically significant increased risk (Figure, top) (46). Among the higher-quality studies, 3 studies showed an HR greater than 1.5; the 2 largest studies found a lower HR, although TEARS (Thyroid Epidemiology Audit and Research Study) was not included in the analysis of the higher-quality studies because of inadequate adjustment for common relevant confounders and enrollment of only participants receiving long-term thyroxine medication. In a random-effects model with the 5 higher-quality studies, the pooled HR of subclinical hyperthyroidism and hip fractures was 1.38 (95% CI, 0.92 to 2.07) without evidence of heterogeneity (P for heterogeneity = 0.82; $I^2 = 0\%$) (Table 3). Pooling estimates from all 7 included studies yielded similar results (Table 3). Including only studies that used a TSH cutoff level less than 0.45 mIU/L yielded an HR of 1.46 (CI, 0.62 to 3.45) for hip fractures. Pooled estimates for a TSH cutoff level of 0.1 mIU/L or less yielded an HR of 2.03 (CI, 0.27 to 15.00) with large CIs because only 2 studies reported such data. Results excluding all thyroid hormone recipients and thereby limiting the analysis to participants with endogenous subclinical hyperthyroidism indicated an increased risk for hip fracture (HR, 2.16 [CI, 0.87 to 5.37]). Pre-defined sensitivity analyses excluding studies that did not include FT$_4$ in their definition of subclinical thyroid dysfunction, with the potential enrollment of participants with overt thyroid disease, yielded a slightly higher fracture risk. Stratified analyses by sex and age did not show statistical significance for interaction. A sensitivity analysis considering our predefined quality measures showed similar results for inclusion of studies using formal adjudication procedures. Results remained similar after excluding 1 study with a case–cohort design. After excluding a study that lacked FT$_4$ measurements, included only thyroxine-treated patients, and therefore compared overtreated participants with those in whom euthyroidism was achieved (14), the HR for hip fractures was 1.43 (CI, 0.99 to 2.06) and the duration of overtreatment was not reported.
**Subclinical Hyperthyroidism and Nonspine Fractures**

All included studies had a pattern of an increased risk for nonspine fractures associated with subclinical hyperthyroidism, although it was not statistically significant (Figure, bottom). The pooled HR, including estimates from the 4 higher-quality studies, was 1.20 (CI, 0.83 to 1.72), with weak evidence for statistical heterogeneity (P for heterogeneity = 0.52; $I^2 = 0\%$). Pooling estimates from all studies and sensitivity analyses yielded similar results (Table 3) to those for the association between subclinical hyperthyroidism and hip fractures.

**Subclinical Hypothyroidism and Fractures**

Most individual studies showed a statistically non significant pattern of an increased risk for hip fractures associated with subclinical hypothyroidism (Appendix Figure 2, available at www.annals.org). Pooled HRs from the higher-quality studies were 1.12 (CI, 0.83 to 1.51) for hip fractures and 1.04 (CI, 0.76 to 1.42) for nonspine fractures, both without evidence for heterogeneity across studies ($P = 0.69$ and 0.88, respectively; $I^2 = 0\%$) (Appendix Figure 2 and Table 4). Pooled estimates from studies with $FT_4$ measurements, which have excluded possibly enrolled participants with overt hypothyroidism, as well as from studies excluding thyroxine recipients, yielded similar results.

**Evaluation of Potential Publication Bias**

The rank correlation tests indicated little evidence of publication bias ($P > 0.05$) for all associations, although these tests are not sensitive due to the small number of studies (42).

**DISCUSSION**

In this meta-analysis of 7 population-based, prospective cohort studies, pooled results from the 5 higher-quality studies indicated that subclinical hyperthyroidism might be associated with an increased risk for hip fractures (HR, 1.38 [CI, 0.92 to 2.07]) and nonspine fractures (HR, 1.20 [CI, 0.83 to 1.72]). When thyroxine recipients were excluded, the HRs for participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) for hip fractures and 1.43 (CI, 0.73 to 2.78) for nonspine fractures. The relationship between subclinical hyperthyroidism and fractures seemed to be stronger among adults with a TSH cutoff level of 0.1 mIU/L or less, which indicated a possible dose–response relationship; however, CIs were large because only 2 studies provided such data. In subclinical hypothyroidism, the risk for fractures did not seem to be increased among the higher-quality studies.

To our knowledge, our study is the first systematic review and meta-analysis to examine the association between subclinical thyroid dysfunction and fracture risk. Our findings are supported by 2 previous meta-analyses of TSH-suppressive thyroxine therapy (25, 26), which found that in postmenopausal women, exogenous subclinical hyperthyroidism was significantly associated with a 0.91% annual decrease in bone mass (25). In addition, interventional studies on endogenous subclinical hyperthyroidism due to nodular goiter showed a 2% annual lower BMD than in postmenopausal women treated with an antithyroid drug or radioiodine (47, 48). In overt hyperthyroidism, a meta-analysis of 5 cohort or case–control studies showed that the risk for fractures normalized after 1 year of antithyroid therapy (9). A recent systematic review on the clinical consequences of variations in thyroid
hormones within the euthyroid reference range found good evidence for increased fracture risk associated with lower euthyroid TSH levels (49).

Different hypotheses have been made about the mechanisms of the association between subclinical hyperthyroidism and fractures. Subclinical hyperthyroidism has been associated with decreased BMD (25, 26) and may contribute to osteoporosis (50), which increases vulnerability to fractures (51). A study showed that thigh muscle strength decreases in subclinical hyperthyroidism and possibly leads to an increased risk for fall-related fractures (52, 53), although data on a direct association between subclinical hyperthyroidism and falls are lacking. The duration of subclinical hyperthyroidism may also play an important role in fracture development (47, 48, 51); however, this is difficult to assess, especially for endogenous subclinical hyperthyroidism (54). The observed lower risk for fractures when combining patients with exogenous and endogenous subclinical hyperthyroidism may be due to a presumably lower risk for fractures in patients with exogenous subclinical hyperthyroidism who may receive a reduced dosing of thyroid hormones, which limits the duration of the dysfunction. We found no evidence of a risk difference for fractures in women compared with men, despite the fact that women—especially postmenopausal women—have an increased risk for osteoporosis. In Americans aged 80 years, the 10-year probability of a hip fracture was 14% for women and 6% for men (55). Because all studies but 1 (35) did not have HRs adjusted for BMD, our analysis did not include BMD. When the Study of Osteoporotic Fractures (35) accounted for BMD, results did not substantially change the association between subclinical hyperthyroidism and fractures. However, the extent to which bone mass mediates the adverse effect of low TSH levels on fracture risk remains uncertain.

Prospective data on the association between subclinical hypothyroidism and fractures are scarce, and studies mainly investigate treated patients. A small randomized study showed a 1.3% reduction in lumbar BMD after 48 weeks of thyroxine treatment for subclinical hypothyroidism compared with placebo (56), and a large registry study in Denmark found an increased fracture risk for participants with overt hypothyroidism up to 4 years after initiation of thyroxine substitution (57). In our meta-analysis, we did not find an increased risk for fractures among participants with subclinical hypothyroidism. However, insufficient data prevented us from doing a sensitivity analysis to assess fracture risk among participants with subclinical hypothyroidism receiving thyroxine (compared with un-treated participants). Overall, we did not find an effect of subclinical hypothyroidism on fractures, but the actual effect of thyroxine therapy on subclinical hypothyroidism cannot be assessed with the present study data.

Our meta-analysis of subclinical thyroid dysfunction and fractures has important strengths. First, by pooling the data of all available studies, we analyzed a total of 1966 hip and 3281 nonspine fractures in more than 50 000 participants, which increased power to detect an association (58). Second, only population-based prospective studies were included. Third, by contacting all principal investigators or coauthors of these 7 studies, we received additional data that allowed us to derive more uniform subgroup and sensitivity analyses.
Our study also has limitations. First, because it is a meta-analysis of observational studies, results have to be interpreted with caution, and potential biases, confounding, and heterogeneity must be carefully investigated (31, 59). The quality of the studies was heterogeneous. Some studies did not adequately adjust for all common potential confounders, which left a risk for residual confounding, and loss to follow-up and missing data were not reported in all studies. To address these limitations, we reported this study according to accepted guidelines for a meta-analysis of observational studies and did sensitivity analyses when appropriate (59). Furthermore, we excluded studies with major limitations from our main analysis and pooled only the 5 higher-quality studies. Second, selection bias may be present. To reduce this possibility, we used broad inclusion criteria and did sensitivity analyses stratified by design characteristics (59). Third, selective reporting cannot be excluded because tests and graphical assessment for publication bias are not sensitive enough owing to the small number of studies included in our meta-analysis (42). Fourth, our analysis included only European or U.S. cohorts, which limits the generalizability to other settings. Fifth, 6 of the 7 studies measured thyroid function at baseline only. Abnormal TSH levels can spontaneously normalize in 20% to 40% of persons after a mean follow-up of 2 to 4 years (60, 61), which may have decreased the potential associations. Sixth, only 4 of the 7 cohorts included the FT$_4$ level and no study included the T$_3$ level in its definition of subclinical thyroid disease. However, excluding studies (14, 35, 36) in a sensitivity analysis that did not include the FT$_4$ level yielded similar results with slightly higher point estimates. Finally, we conducted analyses stratified by age and sex using aggregate data at study level, but we might have missed a significant relationship because of ecological bias (62).

What are the clinical and research implications of these findings? Recent guidelines recommend treatment of subclinical hyperthyroidism in all persons older than 65 years (63), and our findings of a possibly increased fracture risk associated with subclinical hyperthyroidism are consistent with these guidelines, although there are no studies in which treatment resulted in a reduced fracture risk. Given the high prevalence of both osteoporosis and subclinical thyroid dysfunction in our aging populations, our findings may have public health implications. However, because this is a meta-analysis of observational studies, we cannot rule out that our findings are due to reasons other than subclinical thyroid dysfunction. A meta-analysis of individual-participant data that does not have potential aggregation bias could provide more insight through uniform TSH cutoff levels, standardized adjustment for potential confounding factors, and a thorough analysis of subgroups. To prove causality, large randomized, controlled trials are necessary to assess the efficacy of normalizing TSH levels in subclinical thyroid dysfunction associated with fracture risk (64). For subclinical hyperthyroidism, its low prevalence and the requirement for long follow-up make such trials a challenge. But for subclinical hypothyroidism, the ongoing TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) will clarify this issue (65).

In summary, our systematic review indicates that subclinical hyperthyroidism might be associated with an increased risk for hip and nonspine fractures, but additional large, high-quality studies are needed.
Acknowledgment

The authors thank Professor Richard Eastell and Dr. Judith Finigan (University of Sheffield, Sheffield, United Kingdom); Dr. Avantika Waring (University of California, San Francisco, San Francisco, California); Dr. Stephanie Litwack-Harrison (San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California); Professor Graham Leese and Dr. Robert W. Flynn (Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom); Dr. Anders Svare (Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway); Professor Howard Fink (Geriatric Research Education and Clinical Center, Minneapolis Veterans Affairs Medical Center, and Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota); and Professor Anne R. Cappola (Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania) for supplying additional data from their studies.

Financial Support: By the Swiss National Science Foundation (grant SNSF 320030-138267 [Dr. Rodondi]; salary support [Drs. Wirth, Blum, and Baumgartner]; and grant PBLAP3-145870 for salary support [Dr. Collet]) and in part by the Swiss Heart Foundation (Dr. Rodondi).

Appendix

Appendix Figure 1. Summary of evidence search and selection
Studies evaluated for inclusion in the meta-analysis (adapted from PRISMA Statement flow diagram [43]).
* Until 16 March 2014.
† From key articles in the field and contact with the authors (44).
‡ Exclusion criteria included records unrelated to the association between subclinical thyroid dysfunction and fractures or studies without prospective design and thyroid measurement.
§ For list of excluded full-text articles, see the Appendix Table (available at www.annals.org).

### Appendix Table

<table>
<thead>
<tr>
<th>Reason for Exclusion</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason for Exclusion</td>
<td>References</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Reported the same study already selected without additional data to extract</td>
<td>Flynn RWV, Bonellie S, MacDonald TM, Leese GP. Increased risk of osteoporotic fracture in the thyroid population. Pharmacoepidemiology and Drug Safety. 2011;20:S29-S30.</td>
</tr>
<tr>
<td></td>
<td>Garin MC, Arnold AM, Lee JS, Robbins JA; Cappola AR. Subclinical thyroid dysfunction is not associated with hip fracture or lower bone mineral density in older adults. Endocrine Reviews. 2012;33.</td>
</tr>
<tr>
<td>Reason for Exclusion</td>
<td>References</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Increased risk of osteoporosis in thyroid hormone substitution therapy.</td>
<td>Limanová Z, Stepán J. Cas Lek Česk. 1990;129:625-7. [PMID: 2354402]</td>
</tr>
</tbody>
</table>

Only risk within the euthyroid range

- Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010;95:3173-81. [PMID: 20410228]
Appendix Figure 2. Forest plots for subclinical hypothyroidism

CHS = Cardiovascular Health Study; HUNT2 = Nord Trøndelag Health Study 2; MrOS = Osteoporotic Fractures in Men Study; NR = not reported; TEARS = Thyroid Epidemiology Audit and Research Study. **Top.** Risk for hip fractures. **Bottom.** Risk for nonspine fractures.

**References**


32. Hulley, SB.; Cummings, SR.; Browner, WS.; Grady, DG.; Newman, TB. Designing clinical research. 3rd ed. Lippincott Williams & Wilkins; Philadelphia: 2007.

33. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291:228–38. PMID: 14722150. [PubMed: 14722150]


44. van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the


Figure. Forest plots for subclinical hyperthyroidism
CHS = Cardiovascular Health Study; HUNT2 = Nord Trøndelag Health Study 2; MrOS = Osteoporotic Fractures in Men Study; NR = not reported; SOF = Study of Osteoporotic Fractures; TEARS = Thyroid Epidemiology Audit and Research Study. Top. Risk for hip fractures. Bottom. Risk for nonspine fractures.
Table 1
Description and Results of Included Studies for the Effect of Subclinical Thyroid Dysfunction on the Risk for Fractures

<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Population, n</th>
<th>Mean Age, y</th>
<th>TSH Cutoff Level *</th>
<th>Was FT₄ Level Measured and Normal?</th>
<th>Follow-up, y</th>
<th>Fractures (Overall Number of Fractures/Subclinical Hypothyroid; Euthyroid; Subclinical Hyperthyroid Subgroup)</th>
<th>HR (95% CI) †‡</th>
<th>Subclinical Hypothyroid</th>
<th>Subclinical Hyperthyroid</th>
</tr>
</thead>
<tbody>
<tr>
<td>MrOS, 2013 (13)‡</td>
<td>Men, 1513</td>
<td>74</td>
<td>&gt;7.8 mIU/L, 126</td>
<td>Yes</td>
<td>5.3 (mean)  Hip fractures (48/6; 40; 2) Nonspine fractures (30/10; 92; 4)</td>
<td>1.29 (0.49–3.37) 0.89 (0.44–1.79)</td>
<td>2.41 (0.54–10.66) 1.58 (0.85–4.49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotterdam, 2008 (44) and 2013 (45)‡</td>
<td>Both sexes, 1473 (women, 59.3%)</td>
<td>68.5</td>
<td>&gt;4.3 mIU/L, 65</td>
<td>Yes</td>
<td>Yes</td>
<td>9.4 (mean) Hip fractures (53/4; 45; 4) Nonspine fractures (39/12; 234; 13)</td>
<td>1.81 (0.64–5.09) 0.97 (0.54–1.74)</td>
<td>1.61 (0.58–4.51) 1.36 (0.78–2.38)</td>
<td></td>
</tr>
<tr>
<td>CHS, 2010 (12)</td>
<td>Both sexes, 3567 (women, 61.9%)</td>
<td>73</td>
<td>4.5–20.0 mIU/L, 543</td>
<td>Yes</td>
<td>No 9.2% treated</td>
<td>Hip fractures (33/14; 25; 6)</td>
<td>1.23 (0.85–1.77)</td>
<td>1.71 (0.92–3.19)</td>
<td></td>
</tr>
<tr>
<td>HUNT2, 2013 (36)</td>
<td>Both sexes, 25205 (women, 65.9%)</td>
<td>58.2</td>
<td>&gt;3.5 mIU/L, 1877</td>
<td>No ‡‡</td>
<td>Yes</td>
<td>12.5 (median) Hip fractures (1006/99; 876; 31)</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>SOF, 2001 (35)‡</td>
<td>Women, 428 (hip fractures) and 352 (nonspine fractures)‡‡</td>
<td>72</td>
<td>&gt;5.5 mIU/L, NR</td>
<td>No</td>
<td>No (11% treated)</td>
<td>Hip fractures (1390; 114; 11 for a TSH level of 0.1–0.5 mIU/L and 14 for a TSH level ≤0.1 mIU/L) Nonspine fractures (930; 80; 8 for TSH level of 0.1–0.5 mIU/L 5 for TSH level ≤0.1 mIU/L)</td>
<td>1.36 (0.89–3.72) 1.95 (0.85–4.50)</td>
<td>1.89 (1.03–3.52) 1.55 (0.94–2.62)</td>
<td></td>
</tr>
<tr>
<td>TEARS, 2010 (14)‡</td>
<td>Both sexes, all receiving thyroxine, 17 684 (women, 85.9%)</td>
<td>60.5</td>
<td>4.0–20 mIU/L, 1975</td>
<td>No</td>
<td>No (100% treated)</td>
<td>Hip fractures (384/54; 30/12; 148; 60)</td>
<td>1.70 (1.04–2.76) 1.81 (1.38–2.36)</td>
<td>1.08 (0.84–1.39) 1.11 (0.90–1.37)</td>
<td></td>
</tr>
<tr>
<td>Sheffield, 2008 (46)‡</td>
<td>Women, 375</td>
<td>64.6</td>
<td>4.5–20.0 mIU/L, 31</td>
<td>Yes</td>
<td>No (1.7% treated)</td>
<td>Hip fractures (55/14; 8/14)</td>
<td>NR</td>
<td>204 (1.03–4.02) 1.89 (0.89–6.07)</td>
<td></td>
</tr>
</tbody>
</table>

CHS = Cardiovascular Health Study; FT₄ = free thyroxine; HR = hazard ratio; HUNT2 = Nord Trøndelag Health Study 2; MrOS = Osteoporotic Fractures in Men Study; NR = not reported; SOF = Study of Osteoporotic Fractures; TEARS = Thyroid Epidemiology Audit and Research Study; TSH = thyroid-stimulating hormone.

* For the definition of subclinical thyroid dysfunction.
† Most adjusted HR is available. Data from men and women combined (if available).
Unpublished data, including HRs, provided by the authors.

Random sample of the overall cohort.

Data with exclusion of thyroxine recipients available.

Data available for men and women separately.

Estimates reported were stratified by sex, so the authors used fixed effects to combine them before conducting the meta-analysis to avoid double counting a study in the random-effects models.

The FT₄ level was measured if the TSH level was <0.2 mIU/L or >4.0 mIU/L, but participants with biochemically overt thyroid dysfunction were not excluded.

Nested sample of the overall cohort. The authors provided HRs with adjustment for additional confounders, which had not been measured in all women and therefore reduced n. Hip fractures were not included in nonspine fractures.

Lower levels used only for sensitivity analyses.

One hip fracture occurring after a nonspine fracture could not be tracked.

Crude data to prevent overfitting (only 1 hip fracture).
<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Design†</th>
<th>Country</th>
<th>Setting, n</th>
<th>Formal Adjudication Procedures for Fractures‡</th>
<th>Methods for Fracture Ascertainment</th>
<th>Adjudication Without Knowledge of Thyroid Status</th>
<th>Lost to Follow-up, %</th>
<th>Missing Outcome Data, %</th>
<th>Proportional Hazard Assumption</th>
<th>Adjustments</th>
</tr>
</thead>
<tbody>
<tr>
<td>MrOS, 2013 (13)</td>
<td>Random sample of a prospective cohort§</td>
<td>United States</td>
<td>Clinical center, 6</td>
<td>Yes Contact by mail, central adjudication by physician review of radiology reports or radiographs</td>
<td>Yes∥</td>
<td>1.4∥</td>
<td>2∥</td>
<td>Not violated</td>
<td>Age, clinic site, race, BMI, physical activity score, alcohol intake, smoking, and corticosteroid or thyroid hormone use</td>
<td></td>
</tr>
<tr>
<td>Rotterdam, 2008 (44)</td>
<td>Prospective cohort study</td>
<td>The Netherlands</td>
<td>District, 1</td>
<td>Yes Records from general practitioners and the Dutch National Hospital Registration system; review of all coded events by a medical expert</td>
<td>Yes</td>
<td>0.2∥∥</td>
<td>Not violated∥∥</td>
<td>Age, sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHS, 2010 (12)</td>
<td>Prospective cohort study</td>
<td>United States</td>
<td>Community, 4</td>
<td>No∥∥ Telephone interview or clinical visit; hospital records coded with ICD-9</td>
<td>NR</td>
<td>0∥∥</td>
<td>0∥∥</td>
<td>Not violated</td>
<td>Age, race, self-reported health status, frailty status, smoking, alcohol use, height, weight, calcium supplementation, and the use of antosteoporosis and thyroid-altering medication during follow-up</td>
<td></td>
</tr>
</tbody>
</table>

*Proportional hazard assumption was not violated in all studies.†Design refers to the study design used in the study.‡Formal adjudication procedures for fractures include all procedures used to determine whether a fracture was a true fracture or not.∥Methods for fracture ascertainment include all methods used to identify fractures in the study.∥∥Lost to follow-up refers to the percentage of participants who were lost to follow-up during the study.∥∥∥Missing outcome data refers to the percentage of outcome data that were missing in the study.∥∥∥∥Adjustments refer to the adjustments made in the analysis to account for potential confounding factors.∥∥∥∥∥∥Not violated indicates that the proportional hazard assumption was satisfied in all studies.
<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Design&lt;sup&gt;†&lt;/sup&gt;</th>
<th>Country</th>
<th>Setting, n</th>
<th>Formal Adjudication Procedures&lt;sup&gt;‡&lt;/sup&gt; for Fractures&lt;sup&gt;‡&lt;/sup&gt;</th>
<th>Methods for Fracture Ascertainment</th>
<th>Adjudication Without Knowledge of Thyroid Status</th>
<th>Lost to Follow-up, %</th>
<th>Missing Outcome Data, %</th>
<th>Proportional Hazard Assumption</th>
<th>Adjustments</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUNT2, 2013 (36)</td>
<td>Prospective cohort study</td>
<td>Norway</td>
<td>Region, 1</td>
<td>Yes Hospital records (patient administration system), diagnoses coded with ICD-9, ICD-10, SIFP-95, or NCSP, and x-ray descriptions; validation by physicians, health secretaries, and nurses</td>
<td>NR NR NR&lt;sup&gt;‡‡&lt;/sup&gt;</td>
<td>Not violated</td>
<td>Age, sex, BMI, and smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF, 2001 (35)</td>
<td>Nested case–cohort study</td>
<td>United States</td>
<td>Clinical center, 4</td>
<td>Yes Contact by mail; confirmation by review of radiographs or written radiology reports</td>
<td>Yes 1 1</td>
<td>Not violated</td>
<td>Thyroid hormone or oral estrogen use, previous hyperthyroidism, age, self-rated health, smoking, and BMI&lt;sup&gt;∥∥&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEARS, 2010 (14)</td>
<td>Prospective cohort study</td>
<td>Scotland</td>
<td>Region, 1</td>
<td>NR Hospital records; diagnoses coded with ICD-9 or ICD-10</td>
<td>NR NR NR&lt;sup&gt;‡‡&lt;/sup&gt;</td>
<td>Not violated</td>
<td>Age, sex, history of hyperthyroidism, history of osteoporotic fracture, and diabetic status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheffield, 2008 (46)</td>
<td>Prospective cohort study</td>
<td>United Kingdom</td>
<td>Town, 1</td>
<td>NR Questionnaire, general practitioner’s notes, and request forms; confirmation by radiologist’s report or orthopedist’s notes</td>
<td>NR 2 1&lt;sup&gt;§§&lt;/sup&gt;</td>
<td>Not violated&lt;sup&gt;∥∥∥&lt;/sup&gt;</td>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BMI = body mass index; CHS = Cardiovascular Health Study; HUNT2 = Nord Trøndelag Health Study 2; ICD-9 = International Classification of Diseases, Ninth Revision; ICD-10 = International Classification of Diseases, Tenth Revision; MrOS = Osteoporotic Fractures in Men Study; NCSP = Nomesco Classification of Surgical Procedures; NR = not reported; SIFF-95 = third version of the national classification of surgical procedures; SOF = Study of Osteoporotic Fractures; TEARS = Thyroid Epidemiology Audit and Research Study.

* If an article did not clearly mention one of the quality measures (e.g., formal adjudication procedures, adjudication without knowledge of thyroid status, lost to follow-up, or adjustments made), we considered that it had not been done.

† All studies listed were population-based, which was defined as a random sample of the general population.

‡ Defined as having clear criteria for the outcome that was reviewed by experts for each potential case.

§ The sample was chosen randomly at the baseline clinic visit from the 5994 participants included in the MrOS cohort.

∥ Communicated by the investigator.

¶ 214 participants died.

** 3 participants were missing fracture outcomes among those who did not die.

+++ Tested using log–log survival plots.

†† Identification of outcomes by review of hospital records. Missing outcome data cannot formally be excluded because fractures treated in other hospitals might be missing.

§§ Refers to 1 hip fracture occurring after a nonspine fracture that could not be tracked.

∥∥ Assessed by graphical methods (log–log graphs) and the Schoenfeld test.
Table 3
Stratified and Sensitivity Analyses of the Association of Subclinical Hyperthyroidism and the Risk for Fractures

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hip Fractures</th>
<th>Nonspine Fractures</th>
</tr>
</thead>
</table>
|          | Studies, <br>
|          | Pooled HR <br>
|          | (95% CI)      | Studies, <br>
<p>|          | n             | P for Heterogeneity* |
|          |               |                    |
| Higher-quality studies | | |
| Random effects | 1.38 (0.92–2.07) | 5 | 0.82 | 1.20 (0.83–1.72) | 4 | 0.52 |
| Fixed effects | 1.38 (1.04–1.84) | 5 | 1.20 (0.96–1.50) | 4 | 0.52 |
| Estimates with all studies | | |
| Random effects | 1.26 (0.96–1.65) | 7 | 0.36 | 1.16 (0.95–1.50) | 6 | 0.67 |
| Fixed effects | 1.22 (1.01–1.47) | 7 | 1.16 (1.00–1.35) | 6 | 0.67 |
| Stratified and sensitivity analyses | | |
| Definition of subclinical hyperthyroidism | | |
| TSH cutoff level &lt;0.45 mIU/L | 1.46 (0.62–3.45) | 4 | 0.128 | 1.15 (0.75–1.77) | 3 | 0.56 |
| TSH cutoff level ≤0.1 mIU/L | 2.03 (0.27–15.00) | 2 | 0.51 | 1.97 (0.36–10.74) | 2 | 0.94 |
| Exclusion of recipients of thyroxine | 2.16 (0.87–5.37) | 5 | 0.067 | 1.43 (0.73–2.78) | 4 | 0.164 |
| Measurement of FT₄ level and normal FT₄ level | 1.90 (0.86–4.21) | 4 | 0.49 | 1.47 (0.54–3.97) | 3 | 0.87 |
| Stratified by sex‡ | | |
| Women | 1.22 (0.93–1.74) | 6 | 0.44 | 1.19 (0.94–1.49) | 5 | 0.63 |
| Men | 1.35 (0.60–3.03) | 5 | 0.38 | 1.00 (0.44–2.26) | 4 | 0.79 |
| Stratified by mean age at enrollment in the cohorts§ | | |
| &lt;65 y | 1.21 (0.41–3.53) | 3 | 0.140 | 1.11 (0.78–1.59) | 3 | 0.66 |
| &gt;≥65 y | 1.67 (0.80–3.45) | 4 | 0.94 | 1.53 (0.60–3.88) | 3 | 0.78 |
| Characteristics of study quality | | |
| Formal fracture adjudication procedures and adjudication without knowledge of thyroid status | 1.31 (0.78–2.19) | 4 | 0.81 | 1.20 (0.83–1.72) | 4 | 0.52 |
| Studies excluded | | |
| HUNT2 (36), included only hip and forearm fractures as nonspine fractures | 1.40 (0.88–2.21) | 6 | 0.26 | 1.20 (0.92–1.56) | 5 | 0.58 |
| TEARS (14), included only recipients of thyroxine | 1.43 (0.99–2.06) | 6 | 0.48 | 1.22 (0.89–1.66) | 5 | 0.58 |</p>
<table>
<thead>
<tr>
<th>Variable</th>
<th>Hip Fractures</th>
<th>Nonspine Fractures</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pool HR (95% CI)</td>
<td>Studies, n</td>
</tr>
<tr>
<td>SOF (35), used case–cohort design</td>
<td>1.30 (0.90–1.86)</td>
<td>6</td>
</tr>
</tbody>
</table>

FT₄ = free thyroxine; HUNT2 = Nord Trøndelag Health Study 2; HR = hazard ratio; SOF = Study of Osteoporotic Fractures; TEARS = Thyroid Epidemiology Audit and Research Study; TSH = thyroid-stimulating hormone.

* P > 0.10; ratios are homogeneous.
† Did not measure FT₄ or triiodothyronine.
‡ P for interaction (sex) = 0.82 (hip fractures) and 0.69 (nonspine fractures).
§ P for interaction (age) = 0.63 (hip fractures) and 0.53 (nonspine fractures).
### Table 4
Stratified and Sensitivity Analyses of the Association of Subclinical Hypothyroidism and the Risk for Fractures

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hip Fractures</th>
<th></th>
<th>Nonspine Fractures</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pooled HR (95% CI)</td>
<td>Studies, n</td>
<td>P for Heterogeneity</td>
<td>Pooled HR (95% CI)</td>
</tr>
<tr>
<td>Higher-quality studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td>1.12 (0.83–1.51)</td>
<td>4</td>
<td>0.69</td>
<td>1.04 (0.76–1.42)</td>
</tr>
<tr>
<td>Fixed effects</td>
<td>1.12 (0.93–1.35)</td>
<td>4</td>
<td></td>
<td>1.04 (0.90–1.20)</td>
</tr>
<tr>
<td>Estimates with all studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td>1.30 (0.93–1.82)</td>
<td>5</td>
<td>0.157</td>
<td>1.28 (0.79–2.08)</td>
</tr>
<tr>
<td>Fixed effects</td>
<td>1.25 (1.06–1.46)</td>
<td>5</td>
<td></td>
<td>1.20 (1.06–1.36)</td>
</tr>
<tr>
<td>Stratified and sensitivity analyses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definition of subclinical hypothyroidism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusion of recipients of thyroxine</td>
<td>1.10 (0.81–1.50)</td>
<td>4</td>
<td>0.60</td>
<td>1.11 (0.60–2.05)</td>
</tr>
<tr>
<td>Measurement of FT₄ level and normal FT₄ level</td>
<td>1.28 (0.63–2.62)</td>
<td>3</td>
<td>0.79</td>
<td>1.20 (0.39–3.64)</td>
</tr>
<tr>
<td>Stratified by sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>1.29 (0.75–2.21)</td>
<td>4</td>
<td>0.078</td>
<td>1.38 (0.80–2.39)</td>
</tr>
<tr>
<td>Men</td>
<td>1.31 (0.44–3.94)</td>
<td>4</td>
<td>0.017</td>
<td>0.98 (0.43–2.24)</td>
</tr>
<tr>
<td>Stratified by mean age at enrollment in the cohorts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 y</td>
<td>1.32 (0.06–28.04)</td>
<td>2</td>
<td>0.013</td>
<td>1.49 (0.54–4.10)</td>
</tr>
<tr>
<td>≥65 y</td>
<td>1.28 (0.63–2.62)</td>
<td>3</td>
<td>0.79</td>
<td>0.94 (0.05–17.24)</td>
</tr>
<tr>
<td>Characteristics of study quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formal fracture adjudication procedures and adjudication without knowledge of thyroid status</td>
<td>1.08 (0.68–1.73)</td>
<td>3</td>
<td>0.57</td>
<td>1.04 (0.76–1.42)</td>
</tr>
<tr>
<td>Studies excluded</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HUNT2 (36), included only hip and forearm fractures as nonspine fractures</td>
<td>1.49 (1.03–2.14)</td>
<td>4</td>
<td>0.58</td>
<td>1.40 (0.73–2.68)</td>
</tr>
<tr>
<td>TEARS (14), included only recipients of thyroxine</td>
<td>1.12 (0.83–1.51)</td>
<td>4</td>
<td>0.69</td>
<td>1.10 (0.73–1.66)</td>
</tr>
</tbody>
</table>

FT₄ = free thyroxine; HUNT2 = Nord Trøndelag Health Study 2; HR = hazard ratio; TEARS = Thyroid Epidemiology Audit and Research Study.

* P > 0.10; ratios are homogeneous.

*Ann Intern Med. Author manuscript; available in PMC 2015 April 20.*
† $P$ for interaction (sex) = 0.98 (hip fractures) and 0.50 (nonspine fractures).
‡ $P$ for interaction (age) = 0.98 (hip fractures) and 0.77 (nonspine fractures).